Data Show SuperGen's MP-470 Is Safe In Humans

SuperGen Inc.
(Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid
development and commercialization of therapies for solid tumors and
hematological malignancies, announced as part of a series of
presentations at the 2008 AACR Annual Meeting that MP-470, its
clinical-stage multi-targeted tyrosine kinase inhibitor and Rad51
suppressor, is bioavailable and safe in humans (Abstract No. 4083).


Entitled, "MP-470, a potent oral Rad51 suppressor is safe and tolerable
in first-in-human study," the poster highlights data indicating that MP-470
can be safely administered in doses of up to 900 mg per day. Additionally,
it was found that Rad51 expression is modulated in a dose-dependent manner.
This is consistent with preclinical studies where MP-470 was shown to
sensitize cancer cells to DNA damaging agents and radiation therapy through
the suppression of Rad51, which is responsible for repair of DNA double
strand breaks.



"This is the first Rad51 suppressor that has advanced into Phase 1
clinical trials," said Dr. Gregory Berk, SuperGen's Chief Medical Officer.
"These results support the potential use of MP-470 in combination with
DNA-damaging chemotherapies as a direct result of its ability to inhibit
the repair of double stranded DNA breaks. The lack of toxicity observed to
date with MP-470 further supports this clinical development strategy. Later
this year, we expect to report preliminary data on a recently initiated,
multi-arm Phase 1b clinical trial of MP-470 in combination with standard
chemotherapy regimens."



Interim data from the ongoing MP-470 Phase 1 trial was presented. Ten
patients with refractory solid tumors participated in this accelerated
titration study. Doses were started at 100 mg orally once per day and
escalated to 900 mg. No dose limiting toxicities were observed.



Copies of the 2008 AACR Annual Meeting poster presentations will be
available in the pipeline section of SuperGen's Web site supergen.



About SuperGen



Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company
dedicated to the discovery, rapid development and commercialization of
therapies for solid tumors and hematological malignancies. SuperGen is
developing a number of therapeutic anticancer products focused on kinase
and cell signaling inhibitors and DNA methyltransferase inhibitors. For
more information about SuperGen, please visit supergen.



Forward Looking Statements



This news release contains certain "forward-looking" statements within
the meaning of the Private Securities Litigation Reform Act of 1995. These
statements are typically preceded by words such as "believes," "expects,"
"anticipates," "intends," "will," "may," "should," or similar expressions.
These forward-looking statements are not guarantees of future performance
and involve a number of risks and uncertainties that may cause actual
results to differ materially from the results discussed in these
statements. Factors that might cause the company's results to differ
materially from those expressed or implied by such forward-looking
statements include, but are not limited to, the ability to discover,
develop and move target compounds into clinical development and other risks
and uncertainties detailed from time to time in the company's filings with
the Securities and Exchange Commission including its most recently filed
Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of
these forward-looking statements to conform them to actual results.


SuperGen Inc.

supergen